Work

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

Year: 2017

Type: erratum

Source: Investigational New Drugs

DOI: 10.1007/s10637-017-0479-3

Authors: Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim, Howard A. Burris, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, Patricia M. LoRusso

Institutions: Sarah Cannon Research Institute, Tennessee Oncology, Fox Chase Cancer Center, California Pacific Medical Center, AstraZeneca (United States), AstraZeneca (United Kingdom), Yale Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,690

OpenAlex ID: W2725590100

Cites:

Cited by:

Related to: 10